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Inhibition of human immunodeficiency virus type-1 through
autophagy
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Available online at www.sciencedirect.comAs an obligatory intracellular pathogen, human
immunodeficiency virus type-1 (HIV) is dependent upon its
ability to exploit host cell machinery for replication and
dissemination, and to circumvent cellular processes that
prevent its growth. One such intracellular process is
autophagy, a component of the host defense against HIV with
roles in innate immune signaling, adaptive immunity and
intracellular degradation of HIV. During permissive infection,
HIV down-modulates autophagy, promoting its own
replication. Inducers of autophagy can overcome this
suppression and inhibit HIV. This review summarizes recent
advances in understanding the antiviral and replicative roles of
autophagy during HIV infection. Dissecting the molecular
mechanisms by which HIV utilizes autophagy may lead to the
identification of novel drug candidates to treat and potentially
eradicate HIV infection.
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Introduction
Following an acute primary infection, human immuno-
deficiency virus type-1 (HIV) establishes a reservoir of
infected long-lived cells while CD4+ T cells are progress-
ively lost leading to AIDS. Whether HIV establishes true
latency or a persistent infection with continued low-level
viral replication during periods of prolonged viral suppres-
sion remains controversial. However, increasing data
examining occult reservoirs support some continued viral
replication in most persons. As an obligatory intracellular
pathogen, HIV survival is dependent upon its ability to
exploit host cell machinery for replication and dissemination
Open access under CC BY license.www.sciencedirect.com and to evade intrinsic cellular processes and defenses
that may limit viral replication and pathogenesis in-
cluding autophagy — a cell-autonomous innate immune
defense whereby cells eliminate intracellular pathogens
by capture into autophagosomes with subsequent killing
through macroautophagy  (a process sometimes referred
to as xenophagy) [1].
Macroautophagy (hereafter referred to as autophagy) is a
degradation pathway whereby cytosolic double mem-
brane-bound compartments termed autophagosomes
engulf cytoplasmic constituents such as subcellular orga-
nelles and microbial pathogens, including viruses, and
target them for lysosomal degradation. During autophagy,
the physical interaction of the phosphatidylinositol 3-
kinase, catalytic subunit type 3 (PIK3C3) with Beclin-1
(BECN1) forms the PIK3C3 kinase complex producing
phosphatidylinositol-3-phosphate (PI3P), which is essen-
tial for the induction of the nascent phagophore by
recruiting PI3P binding proteins such as RAB5A and
ATG14. To form the autophagosome, two intertwined
conjugation systems play a role. In the first, ATG12 is
activated by ATG7, an E1-like ubiquitin activating
enzyme, transferred to ATG10, an E2-like ubiquitin
conjugating enzyme which covalently conjugates it to
ATG12. ATG12–ATG5 non-covalently binds ATG16L1
and further elongates the phagophore membrane. In the
second, the cytosolic microtubule-associated protein 1
light chain 3 beta (LC3B)-I, encoded by MAP1LC3B, is
converted to LC3B-II by a ubiquitin-like system that
involves ATG7 and ATG3. The ATG12–ATG5-
ATG16L1 complex functions as an E3-like ubiquitin
ligase, ligating LC3B-II to the nascent autophagosome
membrane through phosphatidylethanolamine with the
LC3B-II associated with the inner membrane degraded
after fusion of the autophagosome with lysosomes.
Although the first reports of autophagy during viral infec-
tions appeared in the 1960s [2], the potential significance
of this is only recently being appreciated. An expanding
literature indicates that autophagy, in a virus-specific
manner, may function to both degrade viruses and
promote viral replication. Moreover, autophagy is not
only an important component of the innate immune
system, but also helps to modulate the adaptive immune
system through MHC class I and class II antigen pres-
entation (Figure 1).Current Opinion in Microbiology 2013, 16:349–354
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Modulation of autophagy. Autophagy can be pharmacologically induced in macrophages by various inducers of autophagy such as MTORC1
inhibitors, the Tat-Beclin peptide, drugs acting via inositol 1,4,5-triphosphate, by TLR8 agonists through the induction of the vitamin D pathway, by
vitamin D directly through the induction of CAMP, and by cytokines such as IFNg, which is dependent upon IRGM. The HIV protein Tat inhibits
autophagy through the inihibition of STAT1 phosphorylation and by increasing the secretion of IL10. HIV Nef both increases autophagy through
interactions with IRGM and inhibits autophagy through Beclin-1 (BECN1) sequestration. HIV infection of CD4+ T cells is associated with the initial
induction of autophagy associated with the fusion activity of the HIV gp41 protein.The role of autophagy in HIV pathogenesis has, until
recently, been under appreciated. However, over the past
five years an increasing number of laboratories have
described the interaction of HIV and autophagy. As often
occurs in new areas of investigation, there are contra-
dictory findings. Of note, it is important to differentiate
studies that are performed in continuous transformed cell
lines or with pseudotyped virus from those performed
using primary cells and infectious HIV isolates. Often,
transformed cells are under different autophagic homeo-
stasis than primary cells and may lead to findings that are
not corroborated when evaluated in primary cells. Sim-
ilarly, single-round replication deficient HIV may not
provide a complete picture of cells that are infected with
multiple-round replication competent virus, although
they can help to dissect molecular processes. In this
review, we have summarized many of the key studies
that have been performed, to date, regarding HIV and
autophagy.
HIV subverts autophagy to promote its own replication
Of the more than 35 human autophagy-associated genes
currently known to be involved in autophagy, ten have
been linked with HIV replication. Using a large-scale
small RNAi screen to identify host factors required by
replication competent HIV in a HeLa-derived cell line,
Brass et al. [3] identified more than 250 HIV-dependency
factors. These included four genes involved in the
nucleation and elongation of autophagosomes (ATG7,
MAP1LC3B, ATG12, ATG16L2) and two involved in lyso-
somal function (CLN3 and LAPTM5) that were essential
for HIV replication. In another cell-line model, EekelsCurrent Opinion in Microbiology 2013, 16:349–354 et al. [4] demonstrated that RNAi of PIK3R4, ATG4A,
ATG5 or ATG16 resulted in the inhibition of replication
competent CXCR4-tropic HIV in SupT1 cells. An
additional two groups have demonstrated that HIV repli-
cation in primary cells is inhibited upon autophagy-associ-
ated gene silencing: BECN1 and ATG5 in macrophages
[5,6,7], and BECN1 and ATG7 in monocytes [8].
In agreement with these RNAi studies, the current data
suggest that the early steps of autophagy are important in
HIV replication in cells of the monocyte/macrophage
lineage. Espert et al. [9] demonstrated that autophago-
some accumulation occurs in productively infected
primary macrophages infected through exposure to
chronically infected MOLT-4 effector cells. They found
that virions were only detectable in cells with moderate,
but not high levels of accumulated autophagosomes
suggesting that HIV elicits the induction of autophagy
but blocks its late proteolytic stage. Consistent with these
findings, HIV assembly is thought to occur on endocytic
membranes that intersect with recycling endosomes
[10,11]. HIV Gag-derived proteins colocalize and interact
with LC3B in macrophages, and are present at LC3B-II
enriched membranes suggesting that autophagy may be
involved in Gag processing and the production of nascent
virions [8]. Moreover, the HIV accessory protein Nef
interacts with immunity-associated GTPase family M
(IRGM), which itself interacts with ATG5, ATG10,
LC3B and SH3GLB1, inducing autophagosome for-
mation and enhancing HIV replication [12]. Finally, in
HIV-infected macrophages where the nucleation and
formation of autophagosomes was inhibited usingwww.sciencedirect.com
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Schematic representation of modulation of autophagy by HIV. During the initial stages of infection, HIV or gp120 binding and TLR8 signaling induce
autophagy to promote viral replication. However, during permissive infection autophagy is downregulated through Nef-Beclin interaction and inhibition
of autophagosome acidification promoting viral persistence and cell survival. However, as shown in Figure 1, inducers of autophagy promote
increased autolysosome formation with degradation of HIV.small-molecule chemical inhibitors or RNAi, the pro-
duction of infectious virions was significantly decreased
[7,8,9] (Figure 1).
Although HIV may upregulate autophagy during the
initial stages of primary infection, HIV must control
the antiviral proteolytic and degradative late stages of
autophagy to avoid its degradation (Figure 2). The cur-
rent data suggest that HIV has developed mechanisms to
inhibit autophagic degradation in CD4+ T cells [13] and
cells of the monocyte/macrophage lineage [8]. Kyei et al.
[8] demonstrated that in HIV-infected macrophages,
HIV Nef plays a major role in the inhibition of the
proteolytic stages of autophagy by binding BECN1.
Interestingly, the authors demonstrated that the Nef
174DD motif previously shown to be required for CD4
downregulation and interactions with the V1 domain of
the vacuolar H+-ATPase [14] was required for Nef to act
as an anti-autophagic maturation factor. Moreover, Nef-
deficient HIV was unable to overcome autophagic degra-
dation and thus replicated less efficiently. It is unlikely
that Nef influences H+-ATPase assembly or activity
thereby inhibiting autophagosome acidification or autop-
hago-lysosome fusion as the inhibition of endosome acid-
ification was previously shown to be independent of Nef
[15]. Thus, the protein complex containing Nef and
BECN1 may act through a mechanism other than acid-
ification, possibly through the redistribution of mem-
brane-associated PIK3C3 [8]. A recent study
demonstrated that Nef binds to amino acids 267–284 in
the BECN1 evolutionarily conserved domain [16]. This
is the same region that is necessary and sufficient for
BECN1 to bind GLIPR2 (GAPR-1) [16], a protein that
associates with lipid rafts at the cytosolic leaflet of the
Golgi membrane [17] and that negatively regulates autop-
hagy by sequestering BECN1 to the Golgi complex
(where it is inactive in autophagy) [16]. Whereas Nef
may not alter autophagosome acidification, recent find-
ings from our laboratory suggest that during permissive
infection HIV prevents the fusion of autophagosomeswww.sciencedirect.com with lysosomes through the inhibition of the hepatocyte
growth factor required tyrosine kinase substrate (HGS) by
a yet unidentified mechanism.
HIV infection of CD4+ T cells is associated with the
initial induction of autophagy associated with the fusion
activity of the HIV gp41 protein [18] followed by the
inhibition of autophagy and reduced autophagosome
accumulation during productive infection [9,13,19]. It
is important to note that during permissive infection of
primary cells, HIV down modulates autophagy. Never-
theless, autophagy is never completely abrogated since it
is required for cell survival. However, inducers of autop-
hagy, including amino acid starvation and rapamycin,
overcome the Nef-imposed phagosome maturation block
leading to inhibition of viral replication [13] (Figure 1).
HIV-induced autophagy in bystander cells
HIV infection and the progression to AIDS are charac-
terized by the depletion of CD4+ T cells through apop-
tosis of the uninfected bystander cells and the direct
killing of HIV-infected cells. More recently, HIV has
been shown to influence autophagy in HIV-uninfected
bystander cells. HIV Tat inhibits interferon-g-induced
autophagy induction in uninfected macrophages through
the inhibition of STAT1 phosphorylation [20]. Tat has
also been shown to inhibit autophagy in uninfected
macrophages through binding CXCR4, VEGFR1 and
b-integrins, and through the induction of AKT1, SRC
and IL10 production [21]. As autophagy is an immune
effector mechanism for the targeted destruction of several
intracellular pathogens, the inhibition of autophagy in
bystander macrophages may contribute to the suscepti-
bility of HIV-1-infected patients to tuberculosis and
toxoplasmosis amongst others. Moreover, as autophagy
promotes antigen presentation, the inhibition of autop-
hagy may promote pathogen immune evasion.
In contrast to the effect of Tat on uninfected macro-
phages, HIV Env protein induces apoptosis in uninfectedCurrent Opinion in Microbiology 2013, 16:349–354
352 Innate immunityCD4+ T cells [9,22] and neurons [23] through a mech-
anism involving the accumulation of BECN1 and the
induction of autophagy. Within CD4+ T cells, this is
dependent upon the fusion activity of the HIV gp41
protein [18] regardless of the co-receptor used for HIV
entry [9]. How the fusogenic function of gp41 induces
autophagy in CD4+ T cells and why gp41 induces autop-
hagy in CD4+ T cells but not in macrophages is unknown
[9]. Within the central nervous system, HIV gp120
induces autophagy in neuroblastoma cells [23]. Postmor-
tem brains from HIV encephalitis (HIVE) patients exhi-
bit increased markers of autophagy compared with brains
from HIV infected individuals without HIVE or HIV
uninfected controls [23,24]. However, it remains
unknown whether autophagy proceeds to completion
in these brains or if there is an accumulation of autophagic
proteins without autophagy-related degradation. These
findings, however, provide support for the hypothesis that
the dysregulation of autophagy during HIV infection is
important in the pathogenesis of neuroAIDS [25].
Utilizing autophagy to control HIV pathogenesis
Cells can use autophagy in a number of different antiviral
roles. These include xenophagy, the presentation of
endogenous viral antigens to the major histocompatibilty
complexes and subsequent activation of the adaptive
immune system, and as a mechanism to detect intracellu-
lar pathogens through delivery of viral products to endo-
somal pattern-recognition receptors (PRRs), which
recognize signature molecules of pathogens termed
pathogen-associated molecular patterns (PAMPs).
Recent research has focused on the role of autophagy in
the innate and adaptive immune systems with pharma-
cological inducers, enhancers and inhibitors of autophagy
currently being examined for the treatment of cancer [26],
lymphangioleiomyomatosis, [27], proteinopathies such as
Huntington’s disease [28], and infectious diseases in-
cluding Mycobacterium tuberculosis [5,29] with some cur-
rently in clinical trials. In contrast, despite the strong need
for the development of alternative antiretrovirals due to
the emergence of resistant viruses, the complexity of
current treatment regimens and the toxicity of currently
used antiretrovirals, few studies have examined the use of
pharmacologic enhancers of autophagy in the treatment
of HIV. The induction and modulation of autophagy
through pharmacological means to enhance HIV treat-
ment is attractive. Since autophagy works at the host
cellular level to improve intracellular killing of both
replicating and non-replicating HIV within endosomes,
it has the potential to be used in combination with
antiretrovirals to treat and potentially eradicate HIV.
Moreover, as autophagy is a cellular process, viral resist-
ance is less likely to develop.
Rapamycin, a specific MTOR complex inhibitor and
inducer of autophagy inhibits HIV replication throughCurrent Opinion in Microbiology 2013, 16:349–354 both the downregulation of CCR5 [30] and the induction
of autophagy [7]. Rapamycin has also been found to
inhibit HIV infection in human peripheral blood leuco-
cytes-SCID reconstituted mice [31]. Of interest, rapamy-
cin also works synergistically to enhance the activity of
entry inhibitors such as vicriviroc, aplaviroc and enfuvir-
tide [31]. However, rapamycin has immunosuppressive
and other adverse effects that limit its potential useful-
ness in the treatment of HIV.
A cell-permeable autophagy-inducing peptide, termed
Tat-Beclin-1 derived from the region of BECN1 that
interacts with HIV Nef and conjugated to the basic region
of HIV Tat has recently been found to markedly inhibit
HIV replication in primary human macrophages through
the induction of autophagy through the canonical path-
way with the same magnitude as rapamycin [16]. This
peptide was also able to restrict the in vitro replication of
Sindbis virus, chikungunya virus and West Nile Virus,
and reduced the mortality of mice infected with West
Nile Virus and chikungunya virus [16].
The antimicrobial effects of vitamin D have been well
documented and association studies have linked low
levels of 25-hydroxycholecalciferol (25D3) and/or the
active metabolite 1a,25-dihydroxycholecalciferol
(1,25D3) with increased risk of or severity of infection
with HIV [32,33]. Physiological concentrations of 1,25D3
induces the dose-dependent inhibition of HIV alone and
in Mycobacterium tuberculosis co-infected macrophages that
is dependent upon both the induction of autophagy and
autophagosomal maturation [5,7]. The precise mechan-
ism by which 1,25D3 induces autophagy has yet to be
elucidated, but it is known that it is dependent upon the
human cathelicidin antimicrobial peptide (CAMP). This
conclusion is supported by recent studies demonstrating
that CAMP silencing inhibits 1,25D3-induced autophagy
and significantly lowers the 1,25D3-mediated restriction
of HIV replication and antimycobacterial activities
[5,34]. Endogenous CAMP has been implicated in a
number of cellular functions including the regulation of
inflammatory responses [35] and the formation and matu-
ration of autophagosomes [34]. CAMP has also been
shown to play an important role in the activation of
mitogen activated protein kinases and CEBPB which
contribute to the transcriptional activation of BECN1
and ATG5 in response to 1,25D3 [34]. Moreover, during
autophagy, autophagosomes recruit CAMP through an
AMP kinase, calcium and CAMKK2 dependent mech-
anism where it is involved in microbial killing [34].
Further work is necessary to determine the precise role of
CAMP in autophagy and antiretroviral activity.
Vitamin D has also been implicated in the autophagic
response to PAMPs by PRRs. There are several classes
of PRRs: Toll like receptors (TLRs), retinoic acid-
inducible gene-I-like receptors and nucleotide-bindingwww.sciencedirect.com
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stranded RNA genome of HIV contains multiple PAMPs
that are recognized by endosomal TLR7 in dendritic cells,
and TLR8 in macrophages [36–38]. Upon stimulation,
TLR7/8 agonists activate NFKB1 via MYD88 that leads
to the induction of a cascade of antiviral effector functions
including the induction of autophagy [6,39] and proin-
flammatory cytokines [38]; thus significantly impairing the
permissivity of peripheral blood mononuclear cells to HIV
infection [40]. Interestingly, HIV downregulates IRAK4,
which is essential for virtually all TLR signaling [41]. In
macrophages, the TLR8-mediated inhibition of HIV is
dependent upon both the presence and upregulation of
vitamin D metabolism and the vitamin D (1,25D3) re-
ceptor which induces autophagy through a CAMP de-
pendent mechanism [6]. In the case of plasmacytoid
dendritic cells, the TLR7-mediated expression of the
proinflammatory cytokine interferon-a is dependent upon
the induction of autophagy [42].
Collectively, these studies demonstrate that inducers of
autophagy inhibit HIV replication. Well-controlled
clinical trials are needed to determine if autophagy indu-
cers are of value as adjunctive treatment in HIV-infected
persons. Dissecting the molecular mechanisms by which
HIV utilizes autophagy has the potential to lead to the
identification of novel drug candidates to treat and poten-
tially to eradicate HIV infection, as well as preventing
HIV-related related complications.
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